1. Effect of cilostazol on arteriovenous fistula in hemodialysis patients
- Author
-
Jae Wan Jeon, Hae Ri Kim, Eujin Lee, Jong In Lee, Young Rok Ham, Ki Ryang Na, Kang Wook Lee, Jwa-Jin Kim, and Dae Eun Choi
- Subjects
Fistula arteriovenosa ,Cilostazol ,Fracaso de la maduración ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Background: The maturation and patency of permanent vascular access are critical in patients requiring hemodialysis. Although numerus trials have been attempted to achieve permanently patent vascular access, little have been noticeable. Cilostazol, a phosphodiesterase-3 inhibitor, has been shown to be effective in peripheral arterial disease including vascular injury-induced intimal hyperplasia. We therefore aimed to determine the effect of cilostazol on the patency and maturation of permanent vascular access. Methods: This single-center, retrospective study included 194 patients who underwent arteriovenous fistula surgery to compare vascular complications between the cilostazol (n = 107) and control (n = 87) groups. Results: The rate of vascular complications was lower in the cilostazol group than in the control group (36.4% vs. 51.7%; p = 0.033), including maturation failure (2.8% vs. 11.5%; p = 0.016). The rate of reoperation due to vascular injury after hemodialysis initiation following fistula maturation was also significantly lower in the cilostazol group than in the control group (7.5% vs. 28.7%; p
- Published
- 2021
- Full Text
- View/download PDF